Denosumab as the Treatment of Recalcitrant Tuberculous Pleural Effusion-Associated Hypercalcemia
Denosumab is a human monoclonal antibody that binds to RANKL (receptor activator of nuclear factor-kappa B ligand). It has mainly been used in the treatment of osteoporosis for a variety of causes especially in situations refractory to bisphosphonates or when kidney function is impaired. It is also...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2021-01-01
|
| Series: | Case Reports in Medicine |
| Online Access: | http://dx.doi.org/10.1155/2021/5544848 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832568557064421376 |
|---|---|
| author | Afdhal Afiq Abd Jalil Sharifah Faradila Wan Muhamad Hatta Aimi Fadilah Mohamad Mohammed Fauzi Abdul Rani |
| author_facet | Afdhal Afiq Abd Jalil Sharifah Faradila Wan Muhamad Hatta Aimi Fadilah Mohamad Mohammed Fauzi Abdul Rani |
| author_sort | Afdhal Afiq Abd Jalil |
| collection | DOAJ |
| description | Denosumab is a human monoclonal antibody that binds to RANKL (receptor activator of nuclear factor-kappa B ligand). It has mainly been used in the treatment of osteoporosis for a variety of causes especially in situations refractory to bisphosphonates or when kidney function is impaired. It is also used in cases of malignancy-associated hypercalcemia. There are many causes of hypercalcemia, but only rarely it is associated with granulomatous diseases such as tuberculous pleural effusion. We report a case of hypercalcemia from tuberculous pleural effusion that was initially admitted with left medium abundance pleural effusion and a serum corrected calcium level of 3.48 mmol/L. The calcium level was successfully normalized within 72 hours of subcutaneous denosumab administration after other interventions have failed. |
| format | Article |
| id | doaj-art-30f3899c1b184b76a84c4ea322abf06d |
| institution | Kabale University |
| issn | 1687-9627 1687-9635 |
| language | English |
| publishDate | 2021-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Case Reports in Medicine |
| spelling | doaj-art-30f3899c1b184b76a84c4ea322abf06d2025-02-03T00:58:47ZengWileyCase Reports in Medicine1687-96271687-96352021-01-01202110.1155/2021/55448485544848Denosumab as the Treatment of Recalcitrant Tuberculous Pleural Effusion-Associated HypercalcemiaAfdhal Afiq Abd Jalil0Sharifah Faradila Wan Muhamad Hatta1Aimi Fadilah Mohamad2Mohammed Fauzi Abdul Rani3Department of Internal Medicine, Faculty of Medicine, Universiti Teknologi MARA, Sungai Buloh, Selangor, MalaysiaDepartment of Internal Medicine, Faculty of Medicine, Universiti Teknologi MARA, Sungai Buloh, Selangor, MalaysiaDepartment of Internal Medicine, Faculty of Medicine, Universiti Teknologi MARA, Sungai Buloh, Selangor, MalaysiaDepartment of Internal Medicine, Faculty of Medicine, Universiti Teknologi MARA, Sungai Buloh, Selangor, MalaysiaDenosumab is a human monoclonal antibody that binds to RANKL (receptor activator of nuclear factor-kappa B ligand). It has mainly been used in the treatment of osteoporosis for a variety of causes especially in situations refractory to bisphosphonates or when kidney function is impaired. It is also used in cases of malignancy-associated hypercalcemia. There are many causes of hypercalcemia, but only rarely it is associated with granulomatous diseases such as tuberculous pleural effusion. We report a case of hypercalcemia from tuberculous pleural effusion that was initially admitted with left medium abundance pleural effusion and a serum corrected calcium level of 3.48 mmol/L. The calcium level was successfully normalized within 72 hours of subcutaneous denosumab administration after other interventions have failed.http://dx.doi.org/10.1155/2021/5544848 |
| spellingShingle | Afdhal Afiq Abd Jalil Sharifah Faradila Wan Muhamad Hatta Aimi Fadilah Mohamad Mohammed Fauzi Abdul Rani Denosumab as the Treatment of Recalcitrant Tuberculous Pleural Effusion-Associated Hypercalcemia Case Reports in Medicine |
| title | Denosumab as the Treatment of Recalcitrant Tuberculous Pleural Effusion-Associated Hypercalcemia |
| title_full | Denosumab as the Treatment of Recalcitrant Tuberculous Pleural Effusion-Associated Hypercalcemia |
| title_fullStr | Denosumab as the Treatment of Recalcitrant Tuberculous Pleural Effusion-Associated Hypercalcemia |
| title_full_unstemmed | Denosumab as the Treatment of Recalcitrant Tuberculous Pleural Effusion-Associated Hypercalcemia |
| title_short | Denosumab as the Treatment of Recalcitrant Tuberculous Pleural Effusion-Associated Hypercalcemia |
| title_sort | denosumab as the treatment of recalcitrant tuberculous pleural effusion associated hypercalcemia |
| url | http://dx.doi.org/10.1155/2021/5544848 |
| work_keys_str_mv | AT afdhalafiqabdjalil denosumabasthetreatmentofrecalcitranttuberculouspleuraleffusionassociatedhypercalcemia AT sharifahfaradilawanmuhamadhatta denosumabasthetreatmentofrecalcitranttuberculouspleuraleffusionassociatedhypercalcemia AT aimifadilahmohamad denosumabasthetreatmentofrecalcitranttuberculouspleuraleffusionassociatedhypercalcemia AT mohammedfauziabdulrani denosumabasthetreatmentofrecalcitranttuberculouspleuraleffusionassociatedhypercalcemia |